KINSEY BELL: Open Payments
NPI 1255189098 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,329 in 70 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $159 · 2025 $1,329
Food & beverage: $1,321Education: $9
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $461 |
| AstraZeneca Pharmaceuticals LP | 8 | $214 |
| Novo Nordisk Inc | 9 | $163 |
| Astellas Pharma US Inc | 4 | $78 |
| Lilly USA, LLC | 4 | $76 |
| Eisai Inc. | 1 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| TOLMAR, INC. | 2 | $30 |
| Dexcom, Inc. | 1 | $25 |
| Boston Scientific Corporation | 1 | $22 |
Products named: QULIPTA, VRAYLAR, AIRSUPRA, UBRELVY, Ozempic, Veozah, MOUNJARO, Wegovy.
Industry payments across AZ — which companies pay providers there.
